SCPH
SCPH
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $16.041M ▲ | $25.324M ▼ | $-18.024M ▲ | -112.362% ▲ | $-0.34 ▲ | $-14.294M ▲ |
| Q1-2025 | $11.752M ▼ | $26.038M ▲ | $-19.742M ▼ | -167.988% ▼ | $-0.37 ▲ | $-17.757M ▼ |
| Q4-2024 | $12.15M ▲ | $24.528M ▼ | $-18.845M ▲ | -155.103% ▲ | $-0.42 ▲ | $-17.299M ▲ |
| Q3-2024 | $10.026M ▲ | $24.861M ▲ | $-35.105M ▼ | -350.14% ▼ | $-0.75 ▼ | $-33.25M ▼ |
| Q2-2024 | $8.054M | $20.185M | $-17.09M | -212.193% | $-0.44 | $-14.904M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $40.809M ▼ | $80.255M ▼ | $101.571M ▲ | $-21.316M ▼ |
| Q1-2025 | $57.544M ▼ | $90.963M ▼ | $96.09M ▲ | $-5.127M ▼ |
| Q4-2024 | $75.655M ▼ | $107.519M ▼ | $94.199M ▼ | $13.32M ▼ |
| Q3-2024 | $91.484M ▲ | $125.069M ▲ | $94.36M ▲ | $30.709M ▲ |
| Q2-2024 | $38.504M | $65.458M | $56.208M | $9.25M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-18.024M ▲ | $-16.111M ▲ | $0 | $-624K ▲ | $-16.735M ▲ | $-16.111M ▲ |
| Q1-2025 | $-19.742M ▼ | $-17.139M ▼ | $0 ▲ | $-972K ▼ | $-18.111M ▼ | $-17.139M ▼ |
| Q4-2024 | $-18.845M ▲ | $-15.186M ▲ | $-12K ▼ | $-631K ▼ | $-15.829M ▼ | $-15.198M ▲ |
| Q3-2024 | $-35.105M ▼ | $-17.424M ▲ | $-9K ▼ | $70.413M ▲ | $52.98M ▲ | $-17.433M ▲ |
| Q2-2024 | $-17.09M | $-20.227M | $1K | $283K | $-19.943M | $-20.227M |
About scPharmaceuticals Inc.
https://www.scpharmaceuticals.comscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $16.041M ▲ | $25.324M ▼ | $-18.024M ▲ | -112.362% ▲ | $-0.34 ▲ | $-14.294M ▲ |
| Q1-2025 | $11.752M ▼ | $26.038M ▲ | $-19.742M ▼ | -167.988% ▼ | $-0.37 ▲ | $-17.757M ▼ |
| Q4-2024 | $12.15M ▲ | $24.528M ▼ | $-18.845M ▲ | -155.103% ▲ | $-0.42 ▲ | $-17.299M ▲ |
| Q3-2024 | $10.026M ▲ | $24.861M ▲ | $-35.105M ▼ | -350.14% ▼ | $-0.75 ▼ | $-33.25M ▼ |
| Q2-2024 | $8.054M | $20.185M | $-17.09M | -212.193% | $-0.44 | $-14.904M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $40.809M ▼ | $80.255M ▼ | $101.571M ▲ | $-21.316M ▼ |
| Q1-2025 | $57.544M ▼ | $90.963M ▼ | $96.09M ▲ | $-5.127M ▼ |
| Q4-2024 | $75.655M ▼ | $107.519M ▼ | $94.199M ▼ | $13.32M ▼ |
| Q3-2024 | $91.484M ▲ | $125.069M ▲ | $94.36M ▲ | $30.709M ▲ |
| Q2-2024 | $38.504M | $65.458M | $56.208M | $9.25M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-18.024M ▲ | $-16.111M ▲ | $0 | $-624K ▲ | $-16.735M ▲ | $-16.111M ▲ |
| Q1-2025 | $-19.742M ▼ | $-17.139M ▼ | $0 ▲ | $-972K ▼ | $-18.111M ▼ | $-17.139M ▼ |
| Q4-2024 | $-18.845M ▲ | $-15.186M ▲ | $-12K ▼ | $-631K ▼ | $-15.829M ▼ | $-15.198M ▲ |
| Q3-2024 | $-35.105M ▼ | $-17.424M ▲ | $-9K ▼ | $70.413M ▲ | $52.98M ▲ | $-17.433M ▲ |
| Q2-2024 | $-17.09M | $-20.227M | $1K | $283K | $-19.943M | $-20.227M |
CEO
John H. Tucker
Compensation Summary
(Year 2024)
CEO
John H. Tucker
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Grade Summary
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
6.06M Shares
$34.358M
RUBRIC CAPITAL MANAGEMENT LP
5.102M Shares
$28.928M
WEISS ASSET MANAGEMENT LP
2.882M Shares
$16.339M
BLACKROCK, INC.
2.38M Shares
$13.497M
VANGUARD GROUP INC
2.177M Shares
$12.343M
TUDOR INVESTMENT CORP ET AL
2.15M Shares
$12.191M
KING LUTHER CAPITAL MANAGEMENT CORP
2.128M Shares
$12.068M
HSBC HOLDINGS PLC
1.9M Shares
$10.773M
BLACKROCK INC.
1.769M Shares
$10.028M
MORGAN STANLEY
1.673M Shares
$9.485M
GLAZER CAPITAL, LLC
1.382M Shares
$7.834M
ALPINE ASSOCIATES MANAGEMENT INC.
961.065K Shares
$5.449M
NEWTYN MANAGEMENT, LLC
940.568K Shares
$5.333M
GEODE CAPITAL MANAGEMENT, LLC
892.301K Shares
$5.059M
NANTAHALA CAPITAL MANAGEMENT, LLC
861.277K Shares
$4.883M
STATE STREET CORP
849.279K Shares
$4.815M
NOMURA HOLDINGS INC
736.041K Shares
$4.173M
PERCEPTIVE ADVISORS LLC
583.142K Shares
$3.306M
ODDO BHF ASSET MANAGEMENT SAS
575.052K Shares
$3.261M
ROYAL BANK OF CANADA
500.223K Shares
$2.836M
Summary
Only Showing The Top 20